Preferred Label : Anti-ALPP/ALPPL2/MMAE ADC SGN-ALPV;
NCIt synonyms : Anti-ALPP/ALPPL2/MMAE Antibody-drug Conjugate SGN-ALPV; Anti-ALPP/ALPPL2 ADC SGN-ALPV; Antibody-drug Conjugate SGN-ALPV; ADC SGN-ALPV;
NCIt definition : An antibody-drug conjugate (ADC) composed of h12F3, a humanized immunoglobulin G1
(IgG1) monoclonal antibody directed against the two oncofetal phosphatases alkaline
phosphatase, placental type (ALPP; placental alkaline phosphatase; PLAP), and alkaline
phosphatase, placental like 2 (ALPPL2; alkaline phosphatase, germ cell) conjugated,
via a protease-cleavable peptide linker, to the microtubule-disrupting cytotoxic agent
monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration,
the antibody moiety of anti-ALPP/ALPPL2/MMAE ADC SGN-ALPV targets and binds to either
ALPP or ALPPL2 or ALPP/ALPPL2 dimer on the surface of tumor cells. Upon internalization
and the release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule
polymerization. This results in G2/M phase cell cycle arrest and apoptosis in ALPP
and/or ALPPL2-expressing tumor cells. In addition, SGN-ALPV mediates antibody-dependent
cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
ALPP and ALPPL2, mainly expressed in placenta and testis, form homo- and heterodimers
and play key roles in nucleotide recycling. They are overexpressed on certain tumor
cell types while normal tissue expression of ALPP and ALPPL2 is restricted to placenta
and reproductive tissue.;
Molecule name : SGN ALPV; SGN-ALPV;
NCI Metathesaurus CUI : CL1905211;
Origin ID : C191756;
UMLS CUI : C5784711;
Semantic type(s)
- concept_is_in_subset
- has_target
